On November 15th, 2022, in response to the new mission and requirements proposed in the report of the 20th National Congress of the Party, the National Medical Product Administration held a working conference on promoting foreign trade and investment. After examining the current status of foreign pharmaceutical enterprises, it was determined to further enhance the services to these entities, as well to the projects pertaining to foreign investment. Zhao Junning, member of the Party Leadership Group and deputy director of the NMPA, attended the meeting and delivered a speech.
Zhao said that the NMPA viewed the services to foreign trade & investment with great importance, and issued guidance documents to ensure unhindered deployment of these services, which are in accordance with the general requirements for servicing foreign trade and investment set forth by the 20th National Congress of the Party.
Zhao also stressed that all departments and local administration should further strengthen the service for foreign trade & investment, speed up the review and approval of pharmaceutical and medical device products, especially the supervision of COVID related products, thereby solidly implement key medical foreign investment projects. Of note, adherence to existing guidelines must be ensured to better serve foreign pharma- & medical investment to achieve results; existing communication channels and mechanisms should be made readily available to understand the issues and demands of foreign business associations and foreign-funded enterprises in China; the Central Administration shall provide guidance provincial admins to ensure quality service to key foreign investment projects.
The participating representatives from provincial admins exchanged their experiences and good practices, and defined the goals and measures for future work, with focus on promoting foreign trade and investment in respective region, especially on key foreign investment projects.